Laboratorios Richmond SACIF
BCBA:RICH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
GoldenHome Living Co Ltd
SSE:603180
|
CN |
Laboratorios Richmond SACIF
Long-Term Debt
Laboratorios Richmond SACIF
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Laboratorios Richmond SACIF
BCBA:RICH
|
Long-Term Debt
186.6B
|
CAGR 3-Years
116%
|
CAGR 5-Years
163%
|
CAGR 10-Years
N/A
|
|
Laboratorios Richmond SACIF
Glance View
Laboratorios Richmond SACIF manufactures pharmaceutical products. The company is headquartered in Buenos Aires, Buenos Aires. The company went IPO on 2017-12-22. The firm's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
See Also
What is Laboratorios Richmond SACIF's Long-Term Debt?
Long-Term Debt
186.6B
ARS
Based on the financial report for Dec 31, 2025, Laboratorios Richmond SACIF's Long-Term Debt amounts to 186.6B ARS.
What is Laboratorios Richmond SACIF's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
163%
Over the last year, the Long-Term Debt growth was 49%. The average annual Long-Term Debt growth rates for Laboratorios Richmond SACIF have been 116% over the past three years , 163% over the past five years .
